Esophageal Adenocarcinoma Methods and Protocols

(sharon) #1
163

Barrett’s adenocarcinoma in a mouse xenograft
model. Mol Cancer Ther 12(3):255–263.
https://doi.org/10.1158/1535-7163.
mct-12-0777


  1. Ford SJ, Obeidy P, Lovejoy DB, Bedford M,
    Nichols L, Chadwick C, Tucker O, Lui GY,
    Kalinowski DS, Jansson PJ, Iqbal TH, Alderson
    D, Richardson DR, Tselepis C (2013)
    Deferasirox (ICL670A) effectively inhibits
    esophageal cancer growth in vitro and in vivo.
    Br J Pharmacol 168(6):1316–1328. https://
    doi.org/10.1111/bph.12045

  2. Lange T, Nentwich MF, Luth M, Yekebas E,
    Schumacher U (2011) Trastuzumab has anti-
    metastatic and anti-angiogenic activity in a
    spontaneous metastasis xenograft model of
    esophageal adenocarcinoma. Cancer Lett
    308(1):54–61. https://doi.org/10.1016/j.
    canlet.2011.04.013

  3. Liu DS, Hoefnagel SJ, Fisher OM, Krishnadath
    KK, Montgomery KG, Busuttil RA, Colebatch
    AJ, Read M, Duong CP, Phillips WA, Clemons
    NJ (2016) Novel metastatic models of esopha-
    geal adenocarcinoma derived from FLO-1 cells
    highlight the importance of E-cadherin in can-
    cer metastasis. Oncotarget 7(50):83342–
    83358. https://doi.org/10.18632/
    oncotarget.13391

  4. Sehdev V, Peng D, Soutto M, Washington MK,
    Revetta F, Ecsedy J, Zaika A, Rau TT,
    Schneider-Stock R, Belkhiri A, El-Rifai W
    (2012) The aurora kinase A inhibitor
    MLN8237 enhances cisplatin-induced cell
    death in esophageal adenocarcinoma cells. Mol
    Cancer Ther 11(3):763–774. https://doi.
    org/10.1158/1535-7163.mct-11-0623

  5. Gros SJ, Dohrmann T, Rawnaq T, Kurschat N,
    Bouvet M, Wessels J, Hoffmann RM, Izbicki
    JR, Kaifi JT (2010) Orthotopic fluorescent
    peritoneal carcinomatosis model of esophageal
    cancer. Anticancer Res 30(10):3933–3938

  6. Sicklick JK, Leonard SY, Babicky ML, Tang
    CM, Mose ES, French RP, Jaquish DV, Hoh
    CK, Peterson M, Schwab R, Lowy AM (2014)
    Generation of orthotopic patient- derived xeno-
    grafts from gastrointestinal stromal tumor.
    J Transl Med 12:41. https://doi.
    org/10.1186/1479-5876-12-41

  7. Hassan MS, Awasthi N, Li J, Schwarz MA,
    Schwarz RE, Holzen UV (2017) A novel intra-
    peritoneal metastatic xenograft mouse model
    for survival outcome assessment of esophageal
    adenocarcinoma. PLoS One 12(2):e0171824.
    https://doi.org/10.1371/journal.
    pone.0171824

  8. Garnett MJ, Edelman EJ, Heidorn SJ,
    Greenman CD, Dastur A, Lau KW, Greninger
    P, Thompson IR, Luo X, Soares J, Liu Q, Iorio


F, Surdez D, Chen L, Milano RJ, Bignell GR,
Tam AT, Davies H, Stevenson JA, Barthorpe S,
Lutz SR, Kogera F, Lawrence K, McLaren-
Douglas A, Mitropoulos X, Mironenko T, Thi
H, Richardson L, Zhou W, Jewitt F, Zhang T,
O’Brien P, Boisvert JL, Price S, Hur W, Yang
W, Deng X, Butler A, Choi HG, Chang JW,
Baselga J, Stamenkovic I, Engelman JA,
Sharma SV, Delattre O, Saez-Rodriguez J,
Gray NS, Settleman J, Futreal PA, Haber DA,
Stratton MR, Ramaswamy S, McDermott U,
Benes CH (2012) Systematic identification of
genomic markers of drug sensitivity in cancer
cells. Nature 483(7391):570–575. https://
doi.org/10.1038/nature11005


  1. Wilding JL, Bodmer WF (2014) Cancer cell
    lines for drug discovery and development.
    Cancer Res 74(9):2377–2384. https://doi.
    org/10.1158/0008-5472.can-13-2971

  2. Niu N, Wang L (2015) In vitro human cell line
    models to predict clinical response to antican-
    cer drugs. Pharmacogenomics 16(3):273–285.
    https://doi.org/10.2217/pgs.14.170

  3. Kresty LA, Weh KM, Zeyzus-Johns B, Perez
    LN, Howell AB (2015) Cranberry proanthocy-
    anidins inhibit esophageal adenocarcinoma
    in vitro and in vivo through pleiotropic cell
    death induction and PI3K/AKT/mTOR inac-
    tivation. Oncotarget 6(32):33438–33455.
    https://doi.org/10.18632/oncotarget.5586

  4. Lin YS, Hu L, Yin MC (2017) Apoptotic effects
    of rotundic acid on human esophagus and lung
    cancer cells. Integr Cancer Ther. https://doi.
    org/10.1177/1534735416635275

  5. Boonstra JJ, Tilanus HW, Dinjens WN (2015)
    Translational research on esophageal adenocar-
    cinoma: from cell line to clinic. Dis Esophagus
    28(1):90–96. https://doi.org/10.1111/
    dote.12095

  6. Hasina R, Surati M, Kawada I, Arif Q, Carey
    GB, Kanteti R, Husain AN, Ferguson MK,
    Vokes EE, Villaflor VM, Salgia R (2013) O-6-
    methylguanine-deoxyribonucleic acid methyl-
    transferase methylation enhances response to
    temozolomide treatment in esophageal cancer.
    J Carcinog 12:20. https://doi.
    org/10.4103/1477-3163.120632

  7. Johnson JI, Decker S, Zaharevitz D, Rubinstein
    LV, Venditti JM, Schepartz S, Kalyandrug S,
    Christian M, Arbuck S, Hollingshead M,
    Sausville EA (2001) Relationships between
    drug activity in NCI preclinical in vitro and
    in vivo models and early clinical trials. Br
    J Cancer 84(10):1424–1431. https://doi.
    org/10.1054/bjoc.2001.1796

  8. Kerbel RS (2003) Human tumor xenografts as
    predictive preclinical models for anticancer
    drug activity in humans: better than commonly


Xenograft Models of Esophageal Adenocarcinoma
Free download pdf